(PDF) Sorafenib Combined With HER-2 Targeted Vaccination

Sorafenib Combined With HER-2 Targeted Vaccination Can Promote Effective T Cell Immunity in Vivo

International Immunopharmacology - Netherlands

doi 10.1016/j.intimp.2017.02.028

Full Text

Abstract

Available in full text

Categories

Date

May 1, 2017

Authors

Melek M.E. Sunay

Jeremy B. Foote

James M. Leatherman

Justin P. Edwards

Todd D. Armstrong

Christopher J. Nirschl

Leisha A. Emens

Publisher

Elsevier BV

Related search

Interleukin 2-Diphtheria Toxin Fusion Protein Can Abolish Cell-Mediated Immunity in Vivo.

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

English

T Cell Contact With Ia Antigens on Nonhemopoietic Cells in Vivo Can Lead to Immunity Rather Than Tolerance

Journal of Experimental Medicine

English

Cardiac Toxicity of HER-2 Targeted Regimens

English

CCL16 Enhances the CD8+ and CD4+ T Cell Reactivity to Human Her-2 Elicited by Dendritic Cells Loaded With Rat Ortholog Her-2

International Journal of Immunopathology and Pharmacology

English

Sorafenib With Interleukin-2 vs Sorafenib Alone in Metastatic Renal Cell Carcinoma: The ROSORC Trial

British Journal of Cancer

Cancer Research

English

High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote v 9V 2 T-Cell Chemotaxis and Cytotoxicity in Vivo

Cancer Research

Cancer Research

English

Sustained Antigen Presentation Can Promote an Immunogenic T Cell Response, Like Dendritic Cell Activation

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

English

In Vivo Inhibitory Effect of Suberoylanilide Hydroxamic Acid Combined With Sorafenib on Human Hepatocellular Carcinoma Cells

Brazilian Journal of Pharmaceutical Sciences

English

CD4+ Regulatory T Cell Responses Induced by T Cell Vaccination in Patients With Multiple Sclerosis

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

English